European and North American lung cancer screening experience and implications for pulmonary nodule management

The potential for low dose computed tomography (LDCT) to act as an effective tool in screening for lung cancer is currently the subject of several randomised control trials. It has recently been given prominence by interim results released by the North American National Lung Screening Trial (NLST). Several other trials assessing LDCT as a screening tool are currently underway in Europe, and are due to report their final results in the next few years. These include the NELSON, DLSCT, DANTE, ITALUNG, MILD and LUSI trials. Although slow to instigate a trial of its own, the UK Lung Screen (UKLS) trial will shortly commence. The knowledge gained from the newer trials has mostly reinforced and refined previous concepts that have formed the basis of existing nodule management guidelines. This article takes the opportunity to summarise the main aspects and initial results of the trials presently underway, assess the status of current collaborative efforts and the scope for future collaboration, and analyse observations from these studies that may usefully inform the management of the indeterminate pulmonary nodule. Key Points aEuro cent Low dose CT screening for lung cancer is promising. aEuro cent The effect of LDCT screening on mortality is still uncertain. aEuro cent Several European randomised controlled trials for LDCT are underway. aEuro cent The trials vary in methodology but most compare LDCT to no screening. aEuro cent Preliminary results have reinforced existing nodule management concepts.